AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action

Aardvark Therapeutics (AARD) is facing a proposed securities class action alleging materially misleading statements about ARD-101 safety and trial prospects. After the company voluntarily paused its Phase 3 HERO trial on Feb. 27, 2026, shares fell more than 56%, and following an FDA full clinical hold on May 14, 2026, the stock dropped another 32.1%. The complaint alleges investors were not told ARD-101 was less safe than believed and that reversible cardiac observations (e.g., QRS prolongation) occurred at above-target doses, allegedly overstating Phase 3 and OLE outlooks. Lead plaintiff motion deadline is Oct. 13, 2026.

Analysis

This is less a fresh fundamental shock than a formalization of a damaged equity story. For a single-asset, clinical-stage name, the real economic damage comes from financing optionality: once safety questions force a hold, every dollar of runway gets repriced with heavier dilution, stricter terms, and a much lower probability of follow-on capital at anything resembling IPO valuation.

The second-order loser set is broader than AARD. Post-IPO biotech peers with one shot on goal, safety-sensitive readouts, or heavy dependence on capital markets should see a modest multiple discount as investors demand cleaner tox packages and faster de-risking; XBI is the cleanest proxy for that de-rating. By contrast, larger diversified biotech balance sheets and names with late-stage assets not dependent on a single IND should absorb some relative inflow as capital rotates away from binary risk.

Near term, the lawsuit itself is not the catalyst; the stock already repriced on the hold. The trading path over the next 1-3 months is driven by FDA correspondence, any protocol amendment needed to rescue the program, and whether the company is forced into another financing event before visibility improves. Over 6-18 months, the key falsifier is a credible hold-lift plus data showing the cardiac signal is dose-limited and manageable; absent that, litigation just prolongs the overhang rather than creating new downside by itself.

Key Decisions for Investors

• Short AARD only on strength: fade any 1-2 day relief rally or gap-up into the litigation headline; this is a catalyst to sell, not buy. Risk/reward is favorable only if borrow is available and liquidity supports exit.
• Pair trade: long XBI / short AARD as a sector-neutral expression of 'clean biotech' versus single-asset litigation overhang. Use this only if AARD borrow is tight and you want to isolate idiosyncratic downside.
• Do not add to long exposure in pre-revenue biotech IPOs with unresolved safety signals until FDA posture is clarified; use AARD as a watch item for the broader basket and trim any names that depend on a single Phase 2/3 readout.
• Set an alert for financing risk: any ATM filing, PIPE, going-concern language, or cash burn acceleration in the next 1-2 quarters would confirm the dilution thesis and extend the short window.